SG11201509442RA - 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator - Google Patents
4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulatorInfo
- Publication number
- SG11201509442RA SG11201509442RA SG11201509442RA SG11201509442RA SG11201509442RA SG 11201509442R A SG11201509442R A SG 11201509442RA SG 11201509442R A SG11201509442R A SG 11201509442RA SG 11201509442R A SG11201509442R A SG 11201509442RA SG 11201509442R A SG11201509442R A SG 11201509442RA
- Authority
- SG
- Singapore
- Prior art keywords
- cyclopropylacetyl
- benzenesulfonamide
- pyrrol
- chlorophenyl
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1937MU2013 | 2013-06-03 | ||
PCT/IB2014/061891 WO2014195848A1 (en) | 2013-06-03 | 2014-06-02 | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201509442RA true SG11201509442RA (en) | 2015-12-30 |
Family
ID=50981599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201509442RA SG11201509442RA (en) | 2013-06-03 | 2014-06-02 | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator |
Country Status (22)
Country | Link |
---|---|
US (1) | US9447037B2 (ja) |
EP (1) | EP3004054A1 (ja) |
JP (1) | JP2016520642A (ja) |
CN (1) | CN105263905A (ja) |
AP (1) | AP2015008884A0 (ja) |
AR (1) | AR096462A1 (ja) |
AU (1) | AU2014276436B2 (ja) |
BR (1) | BR112015030171A2 (ja) |
CA (1) | CA2912841A1 (ja) |
CL (1) | CL2015003515A1 (ja) |
CR (1) | CR20150646A (ja) |
CU (1) | CU20150168A7 (ja) |
EA (1) | EA201592247A1 (ja) |
IL (1) | IL242837A0 (ja) |
MA (1) | MA38697A1 (ja) |
MX (1) | MX2015016539A (ja) |
PE (1) | PE20160009A1 (ja) |
PH (1) | PH12015502676A1 (ja) |
SG (1) | SG11201509442RA (ja) |
TW (1) | TW201446243A (ja) |
WO (1) | WO2014195848A1 (ja) |
ZA (1) | ZA201600021B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3233087B1 (en) | 2014-12-16 | 2019-10-02 | Axovant Sciences GmbH | Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors |
AU2016274694A1 (en) | 2015-06-10 | 2018-01-18 | Axovant Sciences Gmbh | Aminobenzisoxazole compounds as agonists of A7-nicotinic acetylcholine receptors |
JP2018523707A (ja) | 2015-08-12 | 2018-08-23 | アクソバント サイエンシズ ゲーエムベーハー | α7−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物 |
SG11201808220VA (en) | 2016-03-22 | 2018-10-30 | Merck Sharp & Dohme | Allosteric modulators of nicotinic acetylcholine receptors |
US11382875B2 (en) * | 2017-04-07 | 2022-07-12 | Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | Methods and compositions for modulating β-amyloid/α7-nAChR interactions |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
CA2561639A1 (en) | 2004-03-29 | 2005-10-06 | Neurosearch A/S | Novel urea derivatives and their medical use |
US20060142349A1 (en) | 2004-12-23 | 2006-06-29 | Pfizer Inc | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor |
US7750011B2 (en) | 2005-02-15 | 2010-07-06 | Neurosearch A/S | Diazabicyclic aryl derivatives and their medical use |
EP1926719B1 (en) | 2005-09-13 | 2017-05-31 | Janssen Pharmaceutica NV | 2-aniline-4-aryl substituted thiazole derivatives |
US20100227869A1 (en) | 2006-02-16 | 2010-09-09 | Dan Peters | Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands |
JO3019B1 (ar) | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
KR20090021165A (ko) | 2006-06-27 | 2009-02-27 | 아보트 러보러터리즈 | 피롤 유도체 및 이의 사용 방법 |
WO2008002956A2 (en) | 2006-06-27 | 2008-01-03 | Abbott Laboratories | Thiazoline and oxazoline derivatives and their methods of use |
CA2695812A1 (en) | 2007-08-08 | 2009-02-12 | Neurosearch A/S | Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors |
CA2701214C (en) | 2007-10-04 | 2016-08-02 | F. Hoffmann-La Roche Ag | Tetrazole-substituted aryl amide derivatives and uses thereof |
JP5362729B2 (ja) | 2007-10-04 | 2013-12-11 | エフ.ホフマン−ラ ロシュ アーゲー | シクロプロピルアリールアミド誘導体及びその使用 |
JO2784B1 (en) | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
AU2009226988B2 (en) | 2008-03-19 | 2013-05-23 | Janssen Pharmaceutica Nv | Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators |
US7786171B2 (en) | 2008-04-04 | 2010-08-31 | Abbott Laboratories | Amide derivatives as positive allosteric modulators and methods of use thereof |
CN102066357B (zh) | 2008-04-17 | 2014-04-09 | 葛兰素集团有限公司 | 作为烟碱型乙酰胆碱受体亚型α71的调节剂的吲哚衍生物 |
JP5486591B2 (ja) | 2008-05-09 | 2014-05-07 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アセチルコリン受容体モジュレーターとしての三置換ピラゾール |
EP2387575B1 (en) | 2009-01-15 | 2013-09-04 | Anvyl, LLC | Alpha7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof |
WO2010130768A1 (en) | 2009-05-14 | 2010-11-18 | Neurosearch A/S | Novel 1,4-diaza-bicyclo[3.2.1]octane derivatives useful as nicotinic acetylcholine receptor modulators |
TWI558398B (zh) | 2009-09-22 | 2016-11-21 | 諾華公司 | 菸鹼乙醯膽鹼受體α7活化劑之用途 |
JO3078B1 (ar) | 2009-11-27 | 2017-03-15 | Janssen Pharmaceutica Nv | مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة |
WO2012104782A1 (en) | 2011-02-03 | 2012-08-09 | Lupin Limited | Pyrrole derivatives used as modulators of alpha7 nachr |
PL2678327T3 (pl) * | 2011-02-23 | 2017-02-28 | Lupin Limited | Pochodne heteroarylowe jako modulatory Alfa 7 NACHR |
AU2012235779B2 (en) | 2011-03-31 | 2017-03-02 | Lupin Limited | Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as Alzheimer's and Parkinson's disease |
EP2729455B1 (en) | 2011-07-05 | 2016-09-14 | Lupin Limited | Biaryl derivatives as nachr modulators |
IN2014MN01756A (ja) | 2012-03-06 | 2015-07-03 | Lupin Ltd | |
EP2945936A1 (en) | 2012-11-12 | 2015-11-25 | Lupin Limited | Thiazole derivatives as alpha 7 nachr modulators |
WO2014111839A1 (en) | 2013-01-16 | 2014-07-24 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
WO2014141091A1 (en) | 2013-03-13 | 2014-09-18 | Lupin Limited | Pyrrole derivatives as alpha 7 nachr modulators |
-
2014
- 2014-05-30 TW TW103118995A patent/TW201446243A/zh unknown
- 2014-06-02 SG SG11201509442RA patent/SG11201509442RA/en unknown
- 2014-06-02 US US14/894,803 patent/US9447037B2/en not_active Expired - Fee Related
- 2014-06-02 BR BR112015030171A patent/BR112015030171A2/pt not_active IP Right Cessation
- 2014-06-02 CN CN201480031584.7A patent/CN105263905A/zh active Pending
- 2014-06-02 MA MA38697A patent/MA38697A1/fr unknown
- 2014-06-02 PE PE2015002547A patent/PE20160009A1/es not_active Application Discontinuation
- 2014-06-02 MX MX2015016539A patent/MX2015016539A/es unknown
- 2014-06-02 WO PCT/IB2014/061891 patent/WO2014195848A1/en active Application Filing
- 2014-06-02 JP JP2016517710A patent/JP2016520642A/ja not_active Withdrawn
- 2014-06-02 EA EA201592247A patent/EA201592247A1/ru unknown
- 2014-06-02 AP AP2015008884A patent/AP2015008884A0/xx unknown
- 2014-06-02 AU AU2014276436A patent/AU2014276436B2/en not_active Ceased
- 2014-06-02 EP EP14732406.5A patent/EP3004054A1/en not_active Withdrawn
- 2014-06-02 CA CA2912841A patent/CA2912841A1/en not_active Abandoned
- 2014-06-03 AR ARP140102165A patent/AR096462A1/es unknown
-
2015
- 2015-11-27 PH PH12015502676A patent/PH12015502676A1/en unknown
- 2015-11-30 IL IL242837A patent/IL242837A0/en unknown
- 2015-12-01 CL CL2015003515A patent/CL2015003515A1/es unknown
- 2015-12-03 CU CUP2015000168A patent/CU20150168A7/es unknown
- 2015-12-08 CR CR20150646A patent/CR20150646A/es unknown
-
2016
- 2016-01-04 ZA ZA2016/00021A patent/ZA201600021B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20160107990A1 (en) | 2016-04-21 |
MX2015016539A (es) | 2016-04-15 |
PE20160009A1 (es) | 2016-02-14 |
PH12015502676A1 (en) | 2016-03-07 |
JP2016520642A (ja) | 2016-07-14 |
EA201592247A1 (ru) | 2016-04-29 |
TW201446243A (zh) | 2014-12-16 |
CU20150168A7 (es) | 2016-06-29 |
BR112015030171A2 (pt) | 2017-07-25 |
EP3004054A1 (en) | 2016-04-13 |
ZA201600021B (en) | 2017-05-31 |
US9447037B2 (en) | 2016-09-20 |
CA2912841A1 (en) | 2014-12-11 |
AP2015008884A0 (en) | 2015-11-30 |
AU2014276436B2 (en) | 2017-03-02 |
CL2015003515A1 (es) | 2016-07-01 |
CR20150646A (es) | 2016-04-07 |
MA38697A1 (fr) | 2017-03-31 |
CN105263905A (zh) | 2016-01-20 |
AR096462A1 (es) | 2015-12-30 |
AU2014276436A1 (en) | 2015-12-17 |
WO2014195848A1 (en) | 2014-12-11 |
IL242837A0 (en) | 2016-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL248350B (en) | Fast-acting insulin preparations | |
ZA201800511B (en) | Rapid-acting insulin compositions | |
PL3233108T3 (pl) | Kompozycje insuliny o szybkim działaniu | |
EP2963068A4 (en) | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, AND OPTICAL ANISOTROPIC BODY | |
IL259824B (en) | History of 2-[3-(azolyl)phenyl]-3,1-thiazole-5-carboxylic acid for use as drugs | |
ZA201600021B (en) | 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator | |
EP2958564A4 (en) | HETERO-AROMATIC COMPOUNDS AS MODULATORS OF PI3 KINASE | |
EP3178859A4 (en) | Polymerizable composition, molded object, and use thereof | |
EP2970171A4 (en) | PROCESSES FOR PURIFYING 5- (HALOMETHY) FURFURAL | |
GB201616843D0 (en) | Polymerizable composition comprising compound having mesogenic group, and polymer thereof | |
SG11201608845PA (en) | Cosmetic composition containing mentha haplocalyx as active ingredient | |
EP3505201A4 (en) | SYRINGE PACKAGING | |
GB2556856B (en) | Band-Fastened, Convenience-Packaging for storing absorbent personal care articles | |
PL3231417T3 (pl) | Odporna na składowanie kompozycja oftalmiczna | |
GB201616880D0 (en) | Compound for use in medicine | |
SG10201609022RA (en) | Secure file storage | |
UA32441S (uk) | Логотип «парамедик» | |
EP3389795A4 (en) | CLOSING BODY CARE COMPOSITION | |
UA31121S (uk) | Упаковка для пасти притиральної «regular» | |
TH170710B (th) | สูตรตำรับต้านการกัดกร่อนที่มีเสถียรภาพการการเก็บรักษา | |
TH1401001431B (th) | สูตรปูนหล่อแบบฟันป้องกันจุลชีพที่มีซีโอไลท์เป็นส่วนประกอบและชิ้นหล่อแบบฟัน จากสูตรดังกล่าว |